A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.
Lists
Only you see this
Abstract
The aim of the present study was to conduct a retrospective analysis of efficacy and safety profiles of azacitidine (AZA) <i>versus.</i> decitabine (DAC) in Chinese patients with intermediate or higher-risk MDS, which was based on two clinical trials in a single center. A total of 40 included MDS patients diagnosed with refractory anemia with excess blast (RAEB) were from two independent clinic trials. Patients in each trial received either AZA (n = 19) or DAC (n = 21) respectively, and the effectiveness as well as the safety profile of the two drugs were compared. Patients treated with AZA showed a comparative efficacy to DAC group with regard to the overall response rate (73.7% <i>versus.</i> 76.2%, <i>P</i> = 0.86), overall survival (median: 19.3 <i>versus.</i> 20.8 months, <i>P</i> = 0.56), progression-free survival (median: 12.3 <i>versus.</i> 9.3 months, <i>P</i> = 0.43) and leukemia-free survival (median: 22.8 <i>versus.</i> 26.6 months, <i>P</i> = 0.62). Patients treated with DAC showed slightly higher incidence of severe hematological adverse events during the whole treatment. Comparing hematological AEs in each observation interval, a trend of higher percentage of neutropenia, leukopenia and anemia as well as treatment delays were seen during the first 6 cycles in the DAC group.
BibTeX
@inproceedings{xu2019retrospective,
author = {Ruohao Xu and Xiaomei Chen and Chengxin Deng and Ping Wu and Minming Li and Suxia Geng and Peilong Lai and Zesheng Lu and Jianyu Weng and Xin Du},
title = {{A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.}},
booktitle = {PubMed},
year = {2019},
}Loading related content...